Acorda Therapeutics (ACOR) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acorda Provides Financial and Pipeline Update for 2015 Second Quarter
July 30, 2015 6:01 AM EDTAMPYRA® (dalfampridine) 2Q 2015 Net Revenue of $105.5 Million; 21% increase over 2Q 2014 AMPYRA Net Sales Guidance for 2015 Narrowed to $410-$420 Million 2015 R&D Guidance Revised to $140-$150 Million
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq:ACOR) today provided a financial and pipeline update for the second quarter ended June 30, 2015.
The... More
